These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32723835)

  • 1. Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.
    Madajewski B; Chen F; Yoo B; Turker MZ; Ma K; Zhang L; Chen PM; Juthani R; Aragon-Sanabria V; Gonen M; Rudin CM; Wiesner U; Bradbury MS; Brennan C
    Clin Cancer Res; 2020 Oct; 26(20):5424-5437. PubMed ID: 32723835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
    Juthani R; Madajewski B; Yoo B; Zhang L; Chen PM; Chen F; Turker MZ; Ma K; Overholtzer M; Longo VA; Carlin S; Aragon-Sanabria V; Huse J; Gonen M; Zanzonico P; Rudin CM; Wiesner U; Bradbury MS; Brennan CW
    Clin Cancer Res; 2020 Jan; 26(1):147-158. PubMed ID: 31515460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization.
    Yoo B; Ma K; Zhang L; Burns A; Sequeira S; Mellinghoff I; Brennan C; Wiesner U; Bradbury MS
    Bioorg Med Chem; 2015 Nov; 23(22):7119-30. PubMed ID: 26462054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells.
    Shen Y; TanTai J
    Drug Des Devel Ther; 2020; 14():4503-4510. PubMed ID: 33122893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer.
    Yuan R; Huang Y; Chan L; He D; Chen T
    ACS Appl Mater Interfaces; 2020 Oct; 12(41):45714-45727. PubMed ID: 32927941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma.
    Aragon-Sanabria V; Aditya A; Zhang L; Chen F; Yoo B; Cao T; Madajewski B; Lee R; Turker MZ; Ma K; Monette S; Chen P; Wu J; Ruan S; Overholtzer M; Zanzonico P; Rudin CM; Brennan C; Wiesner U; Bradbury MS
    Clin Cancer Res; 2022 Jul; 28(13):2938-2952. PubMed ID: 35499557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
    Dal Bello MG; Alama A; Barletta G; Coco S; Truini A; Vanni I; Boccardo S; Genova C; Rijavec E; Biello F; Bottoni G; Sambuceti G; Grossi F
    Int J Cancer; 2015 Dec; 137(12):2947-58. PubMed ID: 26089022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
    PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.